Nazaret Sánchez-Sierra

Nazaret Sánchez-Sierra

Auto-generated profile, based on publicly available information

Nazaret Sánchez-Sierra

Department of Leukemia and Lymphoma, Pediatric Cancer Center Barcelona

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 October 2023 in Cancers
Verified
Journal Article
Open access
PDF file
JMJuan Pablo Muñoz
Juan Pablo Muñoz
CLCristina Larrosa
Cristina Larrosa
SCSaray Chamorro
Saray Chamorro
SPSara Perez-Jaume
Sara Perez-Jaume
MSMargarida Simão-Rafael
Margarida Simão-Rafael
Jaume MoraJaume Mora
Jaume Mora
Patients with high-risk neuroblastoma (HR-NB) who are unable to achieve a complete response (CR) to induction therapy have worse outcomes. We investigated the combination of humanized anti-GD2 mAb naxitamab (Hu3F8), irinotecan (I), temozolomide (T), and sargramostim (GM-CSF)—HITS—against primary resistant HR-NB. Eligibility criteria included having a measurable chemo-resistant disease at the end of induction (EOI) treatment. Patients were excluded if they had progressive disease (PD) during induction. Prior anti-GD2 mAb and/or I/T therapy was permitted. Each cycle, administered four weeks apart, comprised Irinotecan 50 mg/m2/day intravenously (IV) plus Temozolomide 150 mg/m2/day orally (days 1–5); naxitamab 2.25 mg/kg/day IV on days 2, 4, 8 and 10, (total 9 mg/kg or 270 mg/m2 per cycle), and GM-CSF 250 mg/m2/day subcutaneously was used (days 6–10). Toxicity was measured using CTCAE v4.0 and responses through the modified International Neuroblastoma Response Criteria (INRC). Thirty-four patients (median age at treatment initiation, 4.9 years) received 164 (median 4; 1–12) HITS cycles. Toxicities included myelosuppression and diarrhea, which was expected with I/T, and pain and hypertension, expected with naxitamab. Grade ≥3-related toxicities occurred in 29 (85%) of the 34 patients; treatment was outpatient. The best responses were CR = 29% (n = 10); PR = 3% (n = 1); SD = 53% (n = 18); PD = 5% (n = 5). For cohort 1 (early treatment), the best responses were CR = 47% (n = 8) and SD = 53% (n = 9). In cohort 2 (late treatment), the best responses were CR = 12% (n = 2); PR = 6% (n = 1); SD = 53% (n = 9); and PD = 29% (n = 5). Cohort 1 had a 3-year OS of 84.8% and EFS 54.4%, which are statistically significant improvements (EFS p = 0.0041 and OS p = 0.0037) compared to cohort 2. In conclusion, naxitamab-based chemo-immunotherapy is effective against primary chemo-resistant HR-NB, increasing long-term outcomes when administered early during the course of treatment.

10 January 2023 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
NSNazaret Sánchez‐Sierra
Nazaret Sánchez‐Sierra
MPMarta Perez‐Somarriba
Marta Perez‐Somarriba
VSVicente Santa‐Maria
Vicente Santa‐Maria
OCOfelia Cruz
Ofelia Cruz
EGEnric García‐Rey
Enric García‐Rey
JMJulia Marsal
Julia Marsal

20 February 2025 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
NSNazaret Sanchez‐Sierra
Nazaret Sanchez‐Sierra
AAAnna Alonso‐Saladrigues
Anna Alonso‐Saladrigues
SPSara Perez‐Jaume
Sara Perez‐Jaume
CRCristina Rivera‐Perez
Cristina Rivera‐Perez
AFAnna Faura
Anna Faura
SRSusana Rives
Susana Rives

28 April 2025
Verified
Preprint
Open access
VLVicente Santa-Maria Lopez
Vicente Santa-Maria Lopez
AFAnna Felip-Badia
Anna Felip-Badia
MCMarina Caballero-Bellón
Marina Caballero-Bellón
NSNazaret Sánchez-Sierra
Nazaret Sánchez-Sierra
ACAlicia Castañeda
Alicia Castañeda
Jaume MoraJaume Mora
Jaume Mora
Introduction : Neuroblastoma (NB) with central nervous system (CNS) metastases is rare at diagnosis but occurs more often during relapse/progression. Patients with CNS metastases face a dismal prognosis, with no standardized curative treatment available. Novel therapeutic approaches, such as intraventricular radio-immunotherapy with 131 I-Omburtamab (Omb), have been developed. In this study, we report a retrospective, single tertiary center analysis of a 23-year cohort of NB patients with CNS metastases, highlighting current treatment strategies. Patients and Methods : Retrospective data analysis of all NB patients with CNS metastases treated at Hospital Sant Joan de Déu, Barcelona, from January 2000 to January 2023. Patient characteristics at diagnosis, first-line treatment, relapse patterns, and CNS metastasis management were analyzed in search of risk variables and survival outcomes. Results : CNS metastases at relapse were identified in 39/185 (21.1%) patients. Median age at diagnosis was 2.7 years, and 24/39 male. Stage 4 NB with multisite metastases accounted for most cases (92.2%). CNS events occurred predominantly at first relapse (29/39, 74.4%) and with neurological symptoms (23/38, 60.5%). MCYN amplification and concomitant extra-CNS metastases at CNS relapse were associated with poorer overall survival (OS) ( p =0.018 and p =0.0059, respectively). Neurological symptoms upon relapse significantly increased the risk for subsequent CNS events ( p =0.028). Curative-intent of treatment was attempted in 34/39 (87.2%) patients. After adjusting for immortal time bias, RT plus Omb significantly improved OS ( p <0.0001). Conclusions : In our experience, MYCN amplification and concomitant extra-CNS metastases at CNS relapse significantly decrease OS. Multimodal treatment including Omburtamab radioimmunotherapy significantly improves survival outcomes.

30 September 2026 in Journal of Pediatric Hematology/Oncology
Verified
Journal Article
Closed access
GMGeorgina Morón-Cazalilla
Georgina Morón-Cazalilla
MPMarina Pons-Espinal
Marina Pons-Espinal
AAAnna Alonso-Saladrigues
Anna Alonso-Saladrigues
LALaura Arqués
Laura Arqués
NSNazaret Sánchez-Sierra
Nazaret Sánchez-Sierra
ANAntoni Noguera-Julian
Antoni Noguera-Julian
Background: BK virus–associated hemorrhagic cystitis (BKV-HC) is well recognized after hematopoietic stem-cell transplantation but remains poorly described in nontransplanted children with hematological malignancies. Observations: We retrospectively identified 6 children with leukemia or lymphoma who developed BKV-HC over a 17-year period. Dysuria and macroscopic hematuria were the most common manifestations. One patient developed urinary obstruction and acute kidney injury. Median symptom duration was 16 days. Most patients received supportive care, and all but one recovered completely without sequelae. Conclusions: BKV-HC is an uncommon complication in nontransplanted children receiving chemotherapy for hematological malignancies. Clinical outcomes are generally favorable with conservative management.